REGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of “Moderate Buy” by Brokerages

REGENXBIO Inc. (NASDAQ:RGNXGet Free Report) has been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $31.63.

RGNX has been the subject of a number of recent research reports. The Goldman Sachs Group decreased their price objective on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, April 17th. Morgan Stanley upped their price target on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, March 14th. Wall Street Zen raised REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. HC Wainwright cut their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 17th. Finally, Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th.

Read Our Latest Report on RGNX

Insider Buying and Selling

In related news, Director Kenneth T. Mills sold 20,602 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the transaction, the director now directly owns 475,103 shares of the company’s stock, valued at approximately $3,758,064.73. The trade was a 4.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.79% of the stock is currently owned by corporate insiders.

Institutional Trading of REGENXBIO

Large investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC bought a new stake in REGENXBIO in the first quarter worth about $35,000. Brooklyn Investment Group lifted its position in shares of REGENXBIO by 163.7% during the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 3,466 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in REGENXBIO in the 4th quarter worth about $54,000. Dynamic Technology Lab Private Ltd bought a new stake in REGENXBIO in the 4th quarter valued at about $79,000. Finally, Laurion Capital Management LP bought a new position in REGENXBIO during the fourth quarter worth about $79,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Trading Down 4.1%

RGNX opened at $8.39 on Monday. REGENXBIO has a 1-year low of $5.04 and a 1-year high of $15.36. The company has a market cap of $420.84 million, a price-to-earnings ratio of -2.70 and a beta of 1.09. The company’s fifty day moving average price is $8.97 and its two-hundred day moving average price is $7.86.

REGENXBIO (NASDAQ:RGNXGet Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). REGENXBIO had a negative return on equity of 53.29% and a negative net margin of 100.62%. The business had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. As a group, equities analysts forecast that REGENXBIO will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

(Get Free Report

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Featured Articles

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.